MarketVIEW: E.coli (ExPEC) vaccines (CAT: VAMV064)

Product Name : MarketVIEW: E.coli (ExPEC) vaccines
Description : Global vaccine overview
Contents : Executive presentation (.pdf) and forecast model (.xls)
Therapeutic Area : Novel vaccines
Publication date : November 2015
Catalogue No : VAMV064

Background

Extra intestinal pathogenic E.coli (ExPEC) is a member of the Enterobacteriaceae bacterial family. It is a leading cause of healthcare-associated (HCA) infections such as bacteraemia, urinary tract infections, neonatal sepsis and meningitis. For bacteraemias, based on a principal diagnosis from US hospital discharge data, there were an 96,560 E. coli bacteraemias in 2013 compared to 46,140 in 2000, an increase of 109%1. Although the number Streptococcal, Staphylococcal and Pneumococcal bacteraemias also increased over the same time period, in 2009, E. coli overtook Staphylococcus as the leading cause of bacteraemia. Importantly, carbapenem-resistant E. coli is also considered an "urgent" threat according to the US CDC. E.coli is also a common cause of community-acquired, uncomplicated UTIs, which are a common cause of US emergency department and primary care visits. According to NHANES III, around 12% of women reported a UTI in the last 12 months.

Currently there is no vaccine to prevent ExPEC infections. Janssen Pharmaceuticals is co-developing JNJ-860/EcoXyn-4V, a 4-valent “O” antigen conjugate vaccine (the O antigen forms part of the E. coli lipopolysaccharide), currently in Phase II development. Other approaches such as subunit or whole vaccines have under investigation but not currently in active development.

The MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of ExPEC vaccines across major Western to 2035. Indications considered are prevention of invasive ExPEC disease in >18 yrs (risk and non-risk) and prevention of recurrent UTIs in females 18-64 yrs. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon the level of populations targeted by a potential vaccine.

---

1 Van der Mee-Marquet NL et al. Marked increase in incidence for bloodstream infections due to Escherichia coli, a side effect of previous antibiotic therapy in the elderly.
Methodology

VacZine Analytics has closely monitored all significant source material pertaining to E.coli (extra intestinal pathogenic, ExPEC) and related pathogens e.g. hospital associated infections. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by VacZine Analytics in the field of novel bacterial vaccines has also been utilised.

PRODUCT CONTENTS:
Published November 2015 (CAT No: VAMV064)

****This product is composed of a forecast model (.xls) and a summary presentation (.pdf)

Title page
Author’s note
Contents
Executive summary
ExPEC vaccines: Commercial model: key outputs
ExPEC vaccines: sales by scenario (base pricing) to 2030
ExPEC vaccines: sales by scenario (low pricing) to 2030
ExPEC vaccines: sales by scenario (high pricing) to 2030
Modelling commercial potential
The role of an ExPEC vaccine
ExPEC: disease associations
ExPEC vaccine: potential indications
ExPEC vaccine: potential target populations
ExPEC vaccine target product profile (TPP)
Key model assumptions
Key model assumptions: scenarios
Pricing assumptions: disease burden comparisons
Pricing assumptions: bacteraemias - comparator table
ExPEC - Disease background and epidemiology
The pathogen
Pathogenic types
E.coli and bacteraemias
Bacteraemias: hospital admissions - US, 2000-2013
Bacteraemias: by age group US, 2013
Bacteraemias: mortality, United Kingdom
Bacteraemias: UK comparison to other hospital pathogens
Bacteraemias: by age and gender, England
Bacteraemias: sources of, England
Bacteraemias: community-acquired, England
Bacteraemias: France
Bacteraemias: France, clinical characteristics
E.coli: infant sepsis and meningitis
E.coli and healthcare-associated infections
Urinary tract infections, uncomplicated
Urinary tract infections, uncomplicated: US burden
Continued......

Urinary tract infections, uncomplicated: hospitalization
Urinary tract infections, uncomplicated: treatment
Urinary tract infections, uncomplicated: recurrence
Urinary tract infections, uncomplicated: impact
E. coli antibiotic resistance trends
E. coli - antibiotic resistance trends: global dynamics
E. coli - antibiotic resistance trends (WHO report)
EU E. coli - antibiotic resistance trends (1)
EU E. coli - antibiotic resistance trends (2)
ExPEC vaccines: R&D pipeline
Vaccine R&D pipeline: overview
Vaccine R&D pipeline: JNJ-860/EcoXyn-4V
Target risk groups for JNJ-860/EcoXyn-4V vaccine
JNJ-860/EcoXyn-4V vaccine: status
Vaccine R&D pipeline: relevance E. coli O serotypes
Vaccine R&D pipeline: other HAI infection targets
Vaccine R&D pipeline: potential clinical strategy
ExPEC vaccines: methodology
Vaccine coverage rates: case studies
Vaccine coverage rates: private self-pay
Vaccine coverage rates: pneumovax benchmarks
Demographic and epidemiological model inputs
Bibliography

VacZine Analytics
Disclaimer

PAGES: ~67 slides, fully referenced/sourced. Available in .pdf form
PRODUCT COST:

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- **FULL PRODUCT** - USD $9995.00/ GBP £6665.00* (Region license)*

*Indicative rate only. Prevailing rate applied to date of transaction.
*A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

---

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
**VacZine Analytics (R)** and the “spiral logo” are UK Registered Trademarks, 2009


46. Urinary Tract Infection Vaccine. Available at: http://www.sequoiasciences.com/Vaccine.htm
49. Evaluation of a Candidate Vaccine Against Uropathogenic Escherichia coli in Women with a Clinical History of Recurrent Urinary Tract Infection. Available at: https://clinicaltrials.gov/show/NCT02289794
56. MASTA. Pricing. Available at: http://www.masta-travel-health.com/PriceList
59. European Core Health Indicators. Available at: http://ec.europa.eu/health/major_chronic_diseases/indicators/index_en.htm#fragment0
TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein refered to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within thirty days of the invoice date.
7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009